Print pageEmail pageRSS Feeds

We are building a strong, well-run business, structured to deliver sustainable results over the long term.

Along with biotechnology leadership, the ARIAD team is focused on its commitment to deliver long-term value to investors through solid business execution. That means maintaining disciplined cost control, thoughtful capital deployment and the highest standards of corporate governance.

Recent Press Releases
More >>
ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer
ARIAD Announces Initiation of Pivotal Phase 2 ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer
Investor Downloads

Download Documentation Corporate Presentation
Download Documentation ARIAD Presentation at J.P. Morgan Conference
Regulatory Updates
Download Documentation FDA Drug Safety Communication on Iclusig
Download Documentation EMA Recommendations for Changes in use of Iclusig
Iclusig (ponatinib) Data
Download Documentation Ponatinib Phase 1 Update – ASCO 2013
Download Documentation Ponatinib activity against KIT – AACR 2013
Download Documentation Ponatinib activity in FGFR – AACR 2013
Download Documentation Ponatinib activity in RET – AACR 2013
AP26113 Data
Download Documentation AP261113 Phase 1/2 Update – ESMO 2013
Download Documentation AP26113 in ALK and ROS1 - AACR 2013
More >>
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

ARIAD Stock Price: $6.69

Stock Symbol: ARIA

Stock Exchange: NASDAQ

Stock Quote at: 04/15/14

4:00 p.m. ET
(US Dollar)
CHANGE (%) Stock is Down 0.33 (4.70%)
DAY LOW$6.23
52 WK. HIGH$23.00
Minimum 20 minute delay
Refresh quote
You are now leaving this website. If you would like to continue, click Continue.